Drug Profile
JNJ 63709178
Alternative Names: CD123 x CD3 DuoBody; CD123-CD3 DuoBody protein; CNTO 9958; JNJ-63709178; JNJ-9178Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genmab; Janssen Research & Development
- Developer Janssen Research & Development
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Acute myeloid leukaemia
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Spain (IV, Infusion)
- 26 Mar 2021 Janssen Research & Development completes a phase I trial in Acute myeloid leukaemia (Second-line therapy or greater) in Spain and USA (IV) (NCT02715011)
- 28 May 2020 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)